ESR1 and osteoporosis: In two cases, drugs received FDA approval, but no European approval: in 2007, the FDA included the “reduction in risk of invasive breast cancer” in high-risk postmenopausal women in its label for the SERM (selective estrogen receptor modulator) raloxifene, while the corresponding EMA label was restricted to the treatment and prevention of osteoporosis.